Haemoglobinopathy Screening Programmes Offer Flexibility

Sebia introduces two new technologies for newborn screening and adult testing of haemoglobinopathies in clinical diagnostic laboratories. The most common forms of these genetically inherited disorders of red blood cell haemoglobin are Sickle Cell disease and Beta Thalassaemia major. From its leading position in protein electrophoresis technology, Sebia is well equipped to fulfill the growing demand worldwide for national haemoglobinopathy screening programmes.

Sebia offers the broadest choice of multipurpose electrophoresis systems and methods. CAPILLARYS™ 2 Neonat Fast for dry spot, cord blood and packed red cell sampling and CAPILLARYS™ 2 Flex Piercing for whole blood/capped tubes haemoglobin as well as serum and urine testing.

CAPILLARYSTM 2 Flex Piercing offers a comprehensive menu for haemoglobins, protein electrophoresis, immunotyping and CDT (carbohydrate-deficient transferrin). For haemoglobinopathy testing, the new cap-piercing capability streamlines workflow with a high throughput of 37 Hb samples/hour, and maximises biohazard safety. Once primary sample tubes are loaded onto the system, the sample rack is gently inverted to ensure

whole blood samples remain homogeneous and produce accurate results. Positive sample identification ensures full traceability from primary sample tube to final result.

These latest innovations strengthen Sebia’s leadership in the field of electrophoresis technology, and position the company as a key player in haemoglobinopathies diagnosis.